NeuroOne Q1 revenue jumps to $978k; OneRF Ablation System receives FDA clearance

NEUROONE MEDICAL TECHNOLOGIES Corp

2024-Q1 EPS reported -$0.14 revenue$977,649

Product revenue $978k in Q1 fiscal 2024, up from $115k in Q1 2023.
Net loss $3.3M vs $1.7M YoY; cash $2.7M at Dec 31, 2023.
FDA 510(k) clearance for OneRF Ablation System in Dec 2023; limited commercial launch expected Q2 2024.
Zimmer Biomet sales force trained for Evo sEEG; new accounts expected to drive revenue growth.
Raised $2.8M via ATM offering at avg $1.45/share in Dec 2023 – Jan 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

NEUROONE MEDICAL TECHNOLOGIES Corp reported financial results for first quarter fiscal year 2024 ended December 31, 2023.

Period: first quarter fiscal year 2024 ended December 31, 2023
Result: reported results

Exact text from the filing

On February 13, 2024, NeuroOne Medical Technologies Corporation (the “Company”) issued a press release announcing its financial results for the fiscal quarter ended December 31, 2023.

View on SEC.gov

51 earnings releases filed in the last 30 days. Browse all earnings releases →

NEUROONE MEDICAL TECHNOLOGIES Corp filing history →

Source: SEC EDGAR

accession 0001213900-24-013294

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.